Karen Elizabeth Hoffman, M.D., M.H.Sc., M.P.H.

Peer-Reviewed Articles

1. Andring LM, Abu-Gheida I, Bathala T, Yoder AK, Manzar GS, Maldonado JA, Frank SJ, Choi S, Nguyen QN, Hoffman K, McGuire SE, Mok H, Aparicio A, Chapin BF, Tang C. Definitive local therapy for T4 prostate cancer associated with improved local control and survival. BJU Int 132(3):307-313, 2023. e-Pub 2023. PMID: 37057728.
2. Sosa AJ, Thames HD, Sanders JW, Choi SL, Nguyen QN, Mok H, Ron Zhu X, Shah S, Mayo LL, Hoffman KE, Tang C, Lee AK, Pugh TJ, Kudchadker R, Frank SJ. Proton Therapy for the Management of Localized Prostate Cancer: Long-Term Clinical Outcomes at a Comprehensive Cancer Center. Radiother Oncol:109854. e-Pub 2023. PMID: 37597805.
3. Gandhi A, Xu T, DeSnyder SM, Smith GL, Lin R, Barcenas CH, Stauder MC, Hoffman KE, Strom EA, Ferguson S, Smith BD, Woodward WA, Perkins GH, Mitchell MP, Garner D, Goodman CR, Aldrich M, Travis M, Lilly S, Bedrosian I, Shaitelman SF. Prospective, early longitudinal assessment of lymphedema-related quality of life among patients with locally advanced breast cancer: The foundation for building a patient-centered screening program. Breast 68:205-215, 2023. e-Pub 2023. PMID: 36863241.
4. Tallman JE, Wallis CJD, Huang LC, Zhao Z, Penson DF, Koyama T, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Barocas DA, Hoffman KE*. Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer. Prostate Cancer Prostatic Dis 26(1):80-87, 2023. e-Pub 2022. PMID: 35217831.
5. Tallman JE, Wallis CJD, Zhao Z, Huang LC, Penson DF, Koyama T, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Hoffman KE, Barocas DA. Correction to: Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer. Prostate Cancer Prostatic Dis. e-Pub 2023. PMID: 36890265.
6. Tallman JE, Wallis CJD, Huang LC, Zhao Z, Penson DF, Koyama T, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Barocas DA, Hoffman KE*. Correction to: Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer. Prostate Cancer Prostatic Dis 26(1):214, 2023. e-Pub 2023. PMID: 36914851.
7. Samora NL, Wallis CJD, Huang LC, Tallman JE, Zhao Z, Hoffman K, Morgans A, Cooperberg M, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Kaplan S, O'Neil B, Paddock LE, Stroup A, Wu XC, Koyama T, Penson DF, Barocas DA. Association between body mass index and localized prostate cancer management and disease-specific quality of life. BJUI Compass 4(2):223-233, 2023. e-Pub 2022. PMID: 36816144.
8. Solanki AA, Puckett LL, Kujundzic K, Katsoulakis E, Park J, Kapoor R, Hagan M, Kelly M, Palta J, Ballas LK, DeMarco J, Hoffman KE, Lawton CAF, Michalski J, Potters L, Zelefsky M, Kudner R, Dawes S, Wilson E, Sandler H. Consensus Quality Measures and Dose Constraints for Prostate Cancer From the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel. Pract Radiat Oncol 13(2):e149-e165, 2023. e-Pub 2022. PMID: 36522277.
9. De B, Pasalic D, Barocas DA, Wallis CJD, Huang LC, Zhao Z, Koyama T, Tang C, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman KE* . Patient-Reported Outcomes after External Beam Radiotherapy with Low Dose-Rate Brachytherapy Boost versus Radical Prostatectomy for Localized Prostate Cancer: Five-Year Results from a Prospective Comparative Effectiveness Study. J Urol 208(6):101097JU0000000000002902, 2022. e-Pub 2022. PMID: 36006050.
10. De B, Pasalic D, Barocas DA, Wallis CJD, Huang LC, Zhao Z, Koyama T, Tang C, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman KE* . Reply by Authors. J Urol 208(6):1239, 2022. e-Pub 2022. PMID: 36349918.
11. Tallman JE, Wallis CJD, Zhao Z, Huang LC, Penson DF, Koyama T, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Hoffman KE , Barocas DA. Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer. Prostate Cancer Prostatic Dis. e-Pub 2022. PMID: 36482081.
12. Joyce DD, Wallis CJD, Huang LC, Hoffman KE , Zhao Z, Koyama T, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA. The Association between Financial Toxicity and Treatment Regret in Men with Localized Prostate Cancer. JNCI Cancer Spectr 6(6), 2022. e-Pub 2022. PMID: 36255249.
13. Aldrich MB, Rasmussen JC, DeSnyder SM, Woodward WA, Chan W, Sevick-Muraca EM, Mittendorf EA, Smith BD, Stauder MC, Strom EA, Perkins GH, Hoffman KE , Mitchell MP, Barcenas CH, Isales LE, Shaitelman SF. Prediction of breast cancer-related lymphedema by dermal backflow detected with near-infrared fluorescence lymphatic imaging. Breast Cancer Res Treat 195(1):33-41, 2022. e-Pub 2022. PMID: 35816269.
14. Andring LM, Diao K, Sun S, Patel M, Whitman GJ, Schlembach P, Arzu I, Joyner MM, Shaitelman SF, Hoffman K , Stauder MC, Smith BD, Woodward WA. Locoregional Management and Prognostic Factors in Breast Cancer With Ipsilateral Internal Mammary and Axillary Lymph Node Involvement. Int J Radiat Oncol Biol Phys 113(3):552-560, 2022. e-Pub 2022. PMID: 35248602.
15. Luckenbaugh AN, Wallis CJD, Huang LC, Wittmann D, Klaassen Z, Zhao Z, Koyama T, Laviana AA, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Hoffman KE , Penson DF, Barocas DA. Association Between Treatment for Localized Prostate Cancer and Mental Health Outcomes. J Urol 207(5):101097JU0000000000002370, 2022. e-Pub 2022. PMID: 34978488.
16. De B, Fu S, Chen YS, Das P, Ku K, Maroongroge S, Woodhouse KD, Hoffman KE , Nguyen QN, Reed VK, Chen AB, Koong AC, Smith BD, Smith GL. Patient, physician, and policy factors underlying variation in use of telemedicine for radiation oncology cancer care. Cancer Med 11(10):2096-2105, 2022. e-Pub 2022. PMID: 35297210.
17. Hanson SE, Lei X, Roubaud MS, DeSnyder SM, Caudle AS, Shaitelman SF, Hoffman KE , Smith GL, Jagsi R, Peterson SK, Smith BD. Long-term Quality of Life in Patients With Breast Cancer After Breast Conservation vs Mastectomy and Reconstruction. JAMA Surg:e220631. e-Pub 2022. PMID: 35416926.
18. Corrigan KL, Lei X, Ahmad N, Arzu I, Bloom E, Chun SG, Goodman C, Hoffman KE , Joyner M, Mayo L, Mitchell M, Nead KT, Perkins GH, Reed V, Reddy JP, Schlembach P, Shaitelman SF, Stauder MC, Strom EA, Tereffe W, Wiederhold L, Woodward WA, Smith BD. Adoption of Ultrahypofractionated Radiation Therapy in Patients With Breast Cancer. Adv Radiat Oncol 7(2):100877, 2022. e-Pub 2021. PMID: 35387420.
19. Wallis CJD, Huang LC, Zhao Z, Penson DF, Koyama T, Conwill R, Tallman JE, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Barocas DA, Hoffman KE . Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: An assessment of the comparative effectiveness analysis of surgery and radiation (CEASAR) cohort. Urol Oncol 40(2):56.e1-56.e8, 2022. e-Pub 2021. PMID: 34154899.
20. Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE , Stauder MC, Strom EA, Arun BK, Shaitelman SF. Breast radiotherapy-related treatment outcomes in patients with or without germline mutations on multigene panel testing. Int J Radiat Oncol Biol Phys 112(2):437-444, 2022. e-Pub 2021. PMID: 34582940.
21. Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE , Stauder MC, Strom EA, Arun BK, Shaitelman SF. Outcomes after breast radiotherapy in a diverse patient cohort with a germline BRCA1/2 mutation. Int J Radiat Oncol Biol Phys 112(2):426-436, 2022. e-Pub 2021. PMID: 34610390.
22. Chapman B, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA ,Perkins GH, Hoffman KE , Stauder MC ,Strom EA, Arun BK, Shaitelman SF. Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 112(2):426-436, 2022.
23. Wallis CJD, Zhao Z, Huang LC, Penson DF, Koyama T, Kaplan SH, Greenfield S, Luckenbaugh AN, Klaassen Z, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Hoffman KE , Barocas DA. Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer. JAMA Oncol 8(1):50-59, 2022. e-Pub 2021. PMID: 34792527.
24. De B, Lowenstein LM, Corrigan KL, Andring LM, Kuban DA, Cantor SB, Volk RJ, Hoffman KE* . Patients' Preferences for Androgen Deprivation Therapy in the Treatment of Intermediate-Risk Prostate Cancer. MDM Policy Pract 7(2):23814683221137752, 2022. e-Pub 2022. PMID: 36405544.
25. De B, Pasalic D, Barocas DA, Zhao Z, Huang LC, Koyama T, Wallis CJD, Tang C, Penson DF, Hoffman KE. Five-Year Outcomes From a Prospective Comparative Effectiveness Study Evaluating External Beam Radiotherapy With Low Dose-Rate Brachytherapy Boost and Prostatectomy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 111(3S):S74, 2021. PMID: 34700625.
26. Wang L, Poenisch F, Sanders J, Sahoo N, Zhu XR, Ma J, Choi S, Nguyen QN, Mok H, Tang C, McGuire SE, Hoffman KE , Shah SJ, Frank SJ. The Dosimetric Effect of MRI Positive-Contrast Markers vs. Negative-Contrast Fiducial Markers on Proton Radiation. Int J Radiat Oncol Biol Phys 111(3S):e129-e130, 2021. PMID: 34700743.
27. Andring LM, Diao K, Sun SX, Patel MM, Schlembach PJ, Arzu IY, Joyner MM, Shaitelman SF, Hoffman KE , Stauder MC, Smith BD, Woodward WA. Prognostic Factors in Breast Cancer Patients With Clinical N3b (Ipsilateral Internal Mammary and Axillary) Disease. Int J Radiat Oncol Biol Phys 111(3S):e195-e196, 2021. PMID: 34700888.
28. Koontz BF, Hoffman KE, Oyekunle T, George DJ, Zhang T, Berry WR, Lee WR, Harrison MR, Corn PG, Halabi S, Armstrong A. Five Year Results of Short Course Complete Androgen Blockade With Abiraterone Acetate and LHRH Agonist for Unfavorable Intermediate and Favorable High Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 111(3S):e281, 2021. PMID: 34701084.
29. Lowenstein LM, Choi NJ, Hoffman KE, Volk RJ, Loeb S. Factors that Influence Clinicians' Decisions to Decrease Active Surveillance Monitoring Frequency or Transition to Watchful Waiting for Localised Prostate Cancer: A Qualitative Study. BMJ Open 11(11):e048347, 2021. e-Pub 2021. PMID: 34772748.
30. Weng JK, Lei X, Schlembach P, Bloom ES, Shaitelman SF, Arzu IY, Chronowski G, Dvorak T, Grade E, Hoffman K, Perkins G, Reed VK, Shah SJ, Stauder MC, Strom EA, Tereffe W, Woodward WA, Hortobagyi GN, Hunt KK, Buchholz TA, Smith BD. Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation. Int J Radiat Oncol Biol Phys 111(2):360-370, 2021. e-Pub 2021. PMID: 33992718.
31. Dorff TB, O'Neil B, Hoffman KE , Lin DW, Loughlin KR, Dall'Era M. 25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. Urol Oncol 39(9):521-527, 2021. e-Pub 2021. PMID: 34266741.
32. Hoffman KE , Johnstone P. A 25-year perspective on the evolution of radiation treatment of urologic cancers. Urol Oncol 39(9):577-581, 2021. e-Pub 2021. PMID: 34325987.
33. Wallis C, Tallman J, Huang LC, Zhao ZG, Penson D, Koyama T, Conwill R, Goodman M, Hamilton A, Wu XC, Paddock L, Stroup A, Cooperberg M, Hashibe M, O'Neil B, Kaplan S, Greenfield S, Barocas D, Hoffman K. ASSOCIATION BETWEEN PELVIC NODAL RADIOTHERAPY AND PATIENT-REPORTED OUTCOMES AMONG MEN UNDERGOING EXTERNAL-BEAM RADIOTHERAPY FOR PROSTATE CANCER. JOURNAL OF UROLOGY 206:E116-E116, 2021.
34. Pasalic D, Barocas DA, Huang LC, Zhao Z, Koyama T, Tang C, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup AM, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman KE . Five-Year Outcomes from a Prospective Comparative Effectiveness Study Evaluating External Beam Radiotherapy with or without Low Dose-Rate Brachytherapy Boost for Localized Prostate Cancer. Cancer 127(11):1912-1925, 2021. e-Pub 2021. PMID: 33595853.
35. Joyce DD, Wallis CJD, Luckenbaugh AN, Huelster HL, Zhao Z, Hoffman KE , Huang LC, Koyama T, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, Neil BBO, Kaplan SH, Greenfield S, Penson DF, Barocas DA. SEXUAL FUNCTION OUTCOMES OF RADIATION AND ANDROGEN DEPRIVATION THERAPY FOR LOCALIZED PROSTATE CANCER IN MEN WITH GOOD BASELINE FUNCTION. Prostate Cancer Prostatic Dis. e-Pub 2021. PMID: 34108648.
36. Koontz BF, Hoffman KE , Halabi S, Healy P, Anand M, George DJ, Harrison MR, Zhang T, Berry WR, Corn PG, Lee WR, Armstrong AJ. Combination of Radiotherapy and Short-Term Androgen Blockade with Abiraterone Acetate plus Prednisone for Men with High and Intermediate Risk Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 109(5):1271-1278, 2021. e-Pub 2020. PMID: 33259932.
37. Tang C, Lei X, Smith GL, Pan HY, Hoffman KE , Kumar R, Chapin BF, Shih YT, Frank SJ, Smith BD. Influence of Geography on Prostate Cancer Treatment. Int J Radiat Oncol Biol Phys 109(5):1286-1295, 2021. e-Pub 2020. PMID: 33316361.
38. Dinh TT, Mitin T, Bagshaw HP, Hoffman KE , Hwang C, Jeffrey Karnes R, Kishan AU, Liauw SL, Lloyd S, Potters L, Showalter TN, Taira AV, Vapiwala N, Zaorsky NG, D'Amico AV, Nguyen PL, Davis BJ. Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys 109(4):953-963, 2021. e-Pub 2020. PMID: 33127490.
39. De B, Kaiser KW, Ludmir EB, Yeboa DN, Tang C, Hoffman KE , Liao Z, Koong AC, Smith BD. Radiotherapy clinical trial enrollment during the COVID-19 pandemic. Acta Oncol 60(3):1-4, 2021. e-Pub 2020. PMID: 33356801.
40. Pasalic D, Strom EA, Allen PK, Williamson TD, Poenisch F, Amos RA, Woodward WA, Stauder MC, Shaitelman SF, Smith BD, Perkins GH, Tereffe W, Hoffman KE . Proton Accelerated Partial Breast Irradiation: Clinical Outcomes at a Planned Interim Analysis of a Prospective Phase 2 Trial. Int J Radiat Oncol Biol Phys 109(2):441-448, 2021. e-Pub 2020. PMID: 32946965.
41. Reisz PA, Laviana AA, Zhao Z, Huang LC, Koyama T, Conwill R, Hoffman K , Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA. Assessing the Quality of Surgical Care for Clinically Localized Prostate Cancer: Results from the CEASAR Study. J Urol 204(6):101097JU0000000000001198, 2020. e-Pub 2020. PMID: 32568605.
42. Huelster HL, Laviana AA, Joyce DD, Huang LC, Zhao Z, Koyama T, Hoffman KE , Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg M, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA. Radiotherapy after radical prostatectomy: Effect of timing of postprostatectomy radiation on functional outcomes. Urol Oncol 38(12):930.e23-930.e32, 2020. e-Pub 2020. PMID: 32736934.
43. Stone BV, Laviana AA, Luckenbaugh AN, Huang L, Zhao Z, Koyama T, Conwill R, Hoffman K , Joyce DD, Goodman M, Hamilton AS, Wu X, Paddoc LE, Stroup A, Cooperberg MR, Hashibe M, O’Neil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA. Patient-reported financial toxicity associated with contemporary treatment for localized prostate cancer. J Urol. e-Pub 2020. PMID: 33252530.
44. Hoffman KE , Garner D, Koong AC, Woodward WA. Understanding the intersection of working from home and burnout to optimize post-COVID19 work arrangements in radiation oncology. Int J Radiat Oncol Biol Phys 108(2):370-373, 2020. PMID: 32890515.
45. Boyce-Fappiano D, Bathala TK, Ye R, Pasalic D, Gjyshi O, Pezzi TA, Noticewala SS, McGinnis GJ, Maroongroge S, Kuban DA, Nguyen QN, McGuire SE, Hoffman KE , Choi S, Tang C, Kudchadker RJ, Frank SJ. Predictors of urinary toxicity with MRI-assisted radiosurgery for low-dose-rate prostate brachytherapy. Brachytherapy 19(5):574-583, 2020. e-Pub 2020. PMID: 32682778.
46. Abu-Gheida I, Bathala TK, Maldonado JA, Khan M, Anscher MS, Frank SJ, Choi S, Nguyen QN, Hoffman KE , McGuire SE, Kim M, Kuban DA, Aparicio A, Chapin BF, Tang C. Increased Frequency of Mesorectal and Perirectal LN Involvement in T4 Prostate Cancers. Int J Radiat Oncol Biol Phys 107(5):982-985, 2020. e-Pub 2020. PMID: 32353391.
47. Tang C, Lei X, Smith GL, Pan HY, Hess K, Chen A, Hoffman KE , Chapin BF, Kuban DA, Anscher M, Tina Shih YC, Frank SJ, Smith BD. Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data. Pract Radiat Oncol 10(4):282-292, 2020. e-Pub 2020. PMID: 32298794.
48. Bagley AF, Anscher MS, Choi S, Frank SJ, Hoffman KE , Kuban DA, McGuire SE, Nguyen QN, Chapin B, Aparicio A, Pezzi TA, Smith GL, Smith BD, Hess K, Tang C. Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer. JAMA Netw Open 3(3):e201255, 2020. e-Pub 2020. PMID: 32191331.
49. Tang C, Hoffman K , Kuban D. Reply to Multidisciplinary clinics: A possible means to help to eliminate racial disparities in prostate cancer. Cancer. e-Pub 2020. PMID: 32160318.
50. Laviana AA, Zhao Z, Huang LC, Koyama T, Conwill R, Hoffman K , Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA. Development and Internal Validation of a Web-based Tool to Predict Sexual, Urinary, and Bowel Function Longitudinally After Radiation Therapy, Surgery, or Observation. Eur Urol. e-Pub 2020. PMID: 32098731.
51. Tang C, Hoffman KE , Allen PK, Gabel M, Schreiber D, Choi S, Chapin BF, Nguyen QN, Davis JW, Corn P, Logothetis C, Ward J, Frank SJ, Navai N, McGuire SE, Anscher M, Pisters L, Pettaway CA, Kumar R, Linson P, Tripuraneni P, Tomaszewski JJ, Patel AB, Augspurger M, Kuban DA. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer 126(3):506-514, 2020. e-Pub 2019. PMID: 31742674.
52. Hoffman KE, Penson DF, Zhao Z, Huang LC, Conwill R, Laviana AA, Joyce DD, Luckenbaugh AN, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Koyama T, Barocas DA. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA 323(2):149-163, 2020. PMID: 31935027.
53. Laviana AA, Hernandez A, Huang LC, Zhao Z, Koyama T, Conwill R, Hoffman K , Feurer ID, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA. Interpretation of Domain Scores on the EPIC-How Does the Domain Score Translate into Functional Outcomes?. J Urol 202(6):1150-1158, 2019. e-Pub 2019. PMID: 31216252.
54. Milgrom SA, Varghese B, Gladish GW, Choi AD, Dong W, Patel ZS, Chung CC, Rao A, Pinnix CC, Gunther JR, Dabaja BS, Lin SH, Hoffman KE , Huff JL, Slagowski J, Abe JI, Iliescu CA, Banchs J, Yusuf SW, Lopez-Mattei JC. Coronary Artery Dose-Volume Parameters Predict Risk of Calcification After Radiation Therapy. J Cardiovasc Imaging 27(4):268-279, 2019. PMID: 31614398.
55. E.A. Strom, P.K. Allen, T. Williamson, F. Poenisch, R.A. Amos, W.A. Woodward, M.C. Stauder, S.F. Shaitelman, B.D. Smith, G.H. Perkins, W. Tereffe, K.E. Hoffman . Prospectively Assessed Outcomes for Proton Accelerated Partial Breast Irradiation. International Journal of Radiation Oncology Biology Physics 105(1):S193, 2019. e-Pub 2019.
56. Christopherson K, Lei X, Barcenas C, Buchholz TA, Garg N, Hoffman KE, Kuerer HM, Mittendorf E, Perkins G, Shaitelman SF, Smith GL, Stauder M, Strom EA, Tereffe W, Woodward WA, Smith BD. Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement. Int J Radiat Oncol Biol Phys 104(3):574-581, 2019. e-Pub 2019. PMID: 30851348.
57. Pasalic D, Kuban DA, Allen PK, Tang C, Mesko SM, Grant SR, Augustyn AA, Frank SJ, Choi S, Hoffman KE , Nguyen QN, McGuire SE, Pollack A, Anscher MS. Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. International Journal of Radiation Oncology Biology Physics 104(4):790-797, 2019. e-Pub 2019. PMID: 30836166.
58. Singh P, Hoffman K , Schaverien MV, Krause KJ, Butler C, Smith BD, Kuerer HM. Neoadjuvant Radiotherapy to Facilitate Immediate Breast Reconstruction: A Systematic Review and Current Clinical Trials. Ann Surg Oncol 26(10):3312–3320. e-Pub 2019. PMID: 31342362.
59. Lairson DR, Wu CF, Chan W, Fu S, Hoffman KE, Pettaway CA. Mean treatment cost of incident cases of penile cancer for privately insured patients in the United States. Urol Oncol 37(4):294.e17-294.e25, 2019. e-Pub 2019. PMID: 30660492.
60. Logan JK, Jiang J, Shih YT, Lei X, Xu Y, Hoffman KE , Giordano SH, Smith BD. Trends in Radiation for Bone Metastasis During a Period of Multiple National Quality Improvement Initiatives. J Oncol Pract 15(4):e356-e368, 2019. e-Pub 2019. PMID: 30849005.
61. Reichard CA, Hoffman KE , Tang C, Williams SB, Allen PK, Achim MF, Kuban DA, Chapin BF. Radical prostatectomy or radiotherapy for high- and very high-risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment. BJU Int. e-Pub 2019. PMID: 31009137.
62. Morgan SC, Hoffman K , Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline. J Urol 201(3):528-534, 2019. PMID: 30759696.
63. Stecklein SR, Shaitelman SF, Babiera GV, Bedrosian I, Black DM, Ballo MT, Arzu I, Strom EA, Reed VK, Dvorak T, Smith BD, Woodward WA, Hoffman KE , Schlembach PJ, Kirsner SM, Nelson CL, Yang J, Guerra W, Dibaj S, Bloom ES. Prospective Comparison of Toxicity and Cosmetic Outcome After Accelerated Partial Breast Irradiation with Conformal External Beam Radiotherapy or Single-Entry Multilumen Intracavitary Brachytherapy. Pract Radiat Oncol 9(1):e4-e13, 2019. e-Pub 2018. PMID: 30125673.
64. Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, Choueiri TK, Trinh QD, Hoffman KE , Spratt DE, Feng FY, Nguyen PL. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. Eur Urol 75(1):35-41, 2019. e-Pub 2018. PMID: 30554605.
65. Grossberg AJ, Lei X, Xu T, Shaitelman SF, Hoffman KE , Bloom ES, Stauder MC, Tereffe W, Schlembach PJ, Woodward WA, Buchholz TA, Smith BD. Association of Transforming Growth Factor β Polymorphism C-509T With Radiation-Induced Fibrosis Among Patients With Early-Stage Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 4(12):1751-1757, 2018. e-Pub 2018. PMID: 30027292.
66. Morgan SC, Hoffman K , Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. Pract Radiat Oncol 8(6):354-360, 2018. e-Pub 2018. PMID: 30322661.
67. Lee DJ, Zhao Z, Huang LC, Koyoma T, Resnick MJ, Penson DF, Barocas DA, Hoffman KE . Racial Variation in Receipt of Quality Radiation Therapy for Prostate Cancer. Cancer Causes Control 29(CACO-D-17-00464R1):895-899, 2018. e-Pub 2018. PMID: 30099628.
68. Hoffman KE , Voong KR, Levy LB, Allen PK, Choi S, Schlembach PJ, Lee AK, McGuire SE, Nguyen Q, Pugh TJ, Frank SJ, Kudchadker RJ, Du W, Kuban DA. Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer. J Clin Oncol 36(29):JCO2018779868, 2018. e-Pub 2018. PMID: 30106637.
69. Morgan SC, Hoffman K , Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H. Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. J Urol. e-Pub 2018. PMID: 30316897.
70. Shaitelman SF, Lei X, Thompson A, Schlembach P, Bloom ES, Arzu IY, Buchholz D, Chronowski G, Dvorak T, Grade E, Hoffman K , Perkins G, Reed VK, Shah SJ, Stauder MC, Strom EA, Tereffe W, Woodward WA, Amaya DN, Shen Y, Hortobagyi GN, Hunt KK, Buchholz TA, Smith BD. Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial. J Clin Oncol:JCO1800317. e-Pub 2018. PMID: 30379626.
71. Morgan SC, Hoffman K , Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H. Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. J Clin Oncol:JCO1801097. e-Pub 2018. PMID: 30307776.
72. Lee DJ, Barocas DA, Zhao Z, Huang LC, Resnick MJ, Koyoma T, Conwill R, McCollum D, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Penson DF, Hoffman KE . Comparison of Patient-Reported Outcomes After External Beam Radiation Therapy and Combined External Beam with Low-Dose Rate Brachytherapy Boost in Men with Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 102(1):116-126, 2018. e-Pub 2018. PMID: 30102188.
73. Van Wyhe RD, Caudle AS, Shaitelman SF, Perkins GH, Buchholz TA, Hoffman KE , Strom EA, Smith BD, Tereffe W, Woodward WA, Stauder MC. A component of lobular carcinoma in clinically lymph node-negative patients predicts for an increased likelihood of upstaging to pathologic stage III breast cancer. Adv Radiat Oncol 3(3):252-257, 2018. e-Pub 2018. PMID: 30197937.
74. Fang P, He W, Gomez D, Hoffman KE , Smith BD, Giordano SH, Jagsi R, Smith GL. Racial disparities in guideline-concordant cancer care and mortality in the United States. Adv Radiat Oncol 3(3):221-229, 2018. e-Pub 2018. PMID: 30202793.
75. Ovalle V, Strom EA, Shaitelman S, Hoffman K , Amos R, Perkins G, Tereffe W, Smith BD, Stauder M, Woodward W. Proton Partial Breast Irradiation: Detailed Description of Acute Clinico-Radiologic Effects. Cancers (Basel) 10(4), 2018. e-Pub 2018. PMID: 29642467.
76. Hoffman KE . Contemporary Prostate Cancer Radiation Therapy in the United States: Patterns of Care and Compliance with Quality Measures. Practical Radiation Oncology 8(5):307-316, 2018. PMID: 30177030.
77. Dinh KT, Aizer AA, Muralidhar V, Mahal BA, Chen YW, Beard CJ, Choueiri TK, Hoffman KE , Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. Am J Med. e-Pub 2018. PMID: 29555248.
78. Pan HY, Jiang J, Hoffman KE , Tang C, Choi SL, Nguyen QN, Frank SJ, Anscher MS, Shih YT, Smith BD. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. J Clin Oncol:JCO2017755371. e-Pub 2018. PMID: 29561693.
79. Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C, Halberg F, Hoffman K , Horst K, Moran J, Patton C, Perlmutter J, Warren L, Whelan T, Wright JL, Jagsi R. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. e-Pub 2018. PMID: 29545124.
80. Tyson MD, Koyama T, Lee D, Hoffman KE , Resnick MJ, Wu XC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Paddock LE, Stroup A, Chen V, Conwill R, McCollum D, Penson DF, Barocas DA. Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results. Eur Urol. e-Pub 2018. PMID: 29501451.
81. Mahal BA, Chen YW, Sethi RV, Padilla OA, Yang DD, Chavez J, Muralidhar V, Hu JC, Feng FY, Hoffman KE , Martin NE, Spratt DE, Yu JB, Orio PF, Nguyen PL. Travel distance and stereotactic body radiotherapy for localized prostate cancer. Cancer. e-Pub 2017. PMID: 29231964.
82. Avulova S, Zhao Z, Lee D, Huang LC, Koyama T, Hoffman KE , Conwill RM, Wu XC, Chen V, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Paddock LE, Stroup A, Resnick MJ, Penson DF, Barocas DA. The Effect of Nerve Sparing Status on Sexual and Urinary Function: 3-Year Results from the CEASAR Study. J Urol. e-Pub 2017. PMID: 29253578.
83. Yang DD, Krasnova A, Nead KT, Choueiri TK, Hu JC, Hoffman KE , Yu JB, Spratt DE, Feng FY, Trinh QD, Nguyen PL. Androgen Deprivation Therapy and Risk of Rheumatoid Arthritis in Patients with Localized Prostate Cancer. Ann Oncol. e-Pub 2017. PMID: 29267861.
84. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K , Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Sloane RS, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Sanchez EMR, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. e-Pub 2017. PMID: 29097493.
85. Woodward WA, Fang P, Arriaga L, Gao H, Cohen EN, Reuben JM, Valero V, Le-Petross H, Middleton LP, Babiera GV, Strom EA, Tereffe W, Hoffman K , Smith BD, Buchholz TA, Perkins GH. A Phase 2 Study of Preoperative Capecitabine and Concomitant Radiation in Women With Advanced Breast Cancer. Int J Radiat Oncol Biol Phys 99(4):777-783, 2017. e-Pub 2017. PMID: 28843370.
86. Ayoub Z, Strom EA, Ovalle V, Perkins GH, Woodward WA, Tereffe W, Smith BD, Shaitelman SF, Stauder MC, Hoffman KE , DeSnyder SM, Garvey PB, Clemens MW, Barcenas CH, Kuerer HM, Kronowitz S. A 10-Year Experience with Mastectomy and Tissue Expander Placement to Facilitate Subsequent Radiation and Reconstruction. Ann Surg Oncol 24(10):2965-2971, 2017. e-Pub 2017. PMID: 28766219.
87. Blanchard P, Davis JW, Frank SJ, Kim j, Pettaway CA, Pugh TJ, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman KE , Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA. Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU International, 2017. e-Pub 2017. PMID: 28941030.
88. Weiss A, Mittendorf EA, DeSnyder SM, Hwang RF, Bea V, Bedrosian I, Hoffman K , Adrade B, Sahin AA, Kuerer HM, Hunt KK, Caudle AS. Expanding Implementation of ACOSOG Z0011 in Surgeon Practice. Clin Breast Cancer. e-Pub 2017. PMID: 29100726.
89. Frank SJ, Pugh TJ, Blanchard P, Mahmood U, Graber WJ, Kudchadker RJ, Davis JW, Kim J, Choi H, Troncoso P, Kuban DA, Choi S, McGuire S, Hoffman KE , Chen HC, Wang X, Swanson DA. Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. Int J Radiat Oncol Biol Phys. e-Pub 2017. PMID: 29229325.
90. Williams SB, Huo J, Chapin BF, Smith BD, Hoffman KE . Impact of urologists' ownership of radiation equipment in the treatment of prostate cancer. Prostate Cancer Prostatic Dis 20(3):300-304, 2017. e-Pub 2017. PMID: 28349981.
91. Yang DD, Muralidhar V, Mahal BA, Nezolosky MD, Labe SA, Vastola ME, Boldbaatar N, King MT, Martin NE, Orio PF, Choueiri TK, Trinh QD, Den RB, Spratt DE, Hoffman KE , Feng FY, Nguyen PL. Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Urol Oncol 35(9):542.e25-542.e32, 2017. e-Pub 2017. PMID: 28533151.
92. Tyson MD, Alvarez J, Koyama T, Hoffman KE , Resnick MJ, Wu XC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Paddock LE, Stroup A, Chen VW, Penson DF, Barocas DA. Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study. Eur Urol 72(2):307-314, 2017. e-Pub 2016. PMID: 27816300.
93. Williams SB, Duan Z, Chamie K, Hoffman KE , Smith BD, Hu JC, Shah JB, Davis JW, Giordano SH. Risk of hospitalisation after primary treatment for prostate cancer. BJU Int 120(1):48-55, 2017. e-Pub 2016. PMID: 27561186.
94. Voong KR, Lal LS, Kuban DA, Pugh TJ, Swint JM, Godby J, Choi S, Lee AK, Schlembach PJ, Frank SJ, McGuire SE, Hoffman KE . Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial. Adv Radiat Oncol 2(3):249-258, 2017. e-Pub 2017. PMID: 29114589.
95. Fang P, He W, Gomez DR, Hoffman KE , Smith BD, Giordano SH, Jagsi R, Smith GL. Influence of Age on Guideline-Concordant Cancer Care for Elderly Patients in the United States. Int J Radiat Oncol Biol Phys 98(4):748-757, 2017. e-Pub 2017. PMID: 28366580.
96. Basourakos SP, Hoffman K , Kim J. Active surveillance in prostate cancer: new efforts, new voices, new hope. BJU Int 120(1):4-5, 2017. PMID: 28621062.
97. Yang DD, Muralidhar V, Mahal BA, Labe SA, Nezolosky MD, Vastola ME, King MT, Martin NE, Orio PF, Choueiri TK, Trinh QD, Spratt DE, Hoffman KE , Feng FY, Nguyen PL. National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 98(2):338-343, 2017. e-Pub 2017. PMID: 28463152.
98. Yang DD, Mahal BA, Muralidhar V, Nezolosky MD, Vastola ME, Labe SA, Boldbaatar N, King MT, Martin NE, Orio PF, Beard CJ, Hoffman KE , Trinh QD, Spratt DE, Feng FY, Nguyen PL. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer. Eur Urol Focus. e-Pub 2017. PMID: 28753811.
99. Williams SB, Huo J, Chamie K, Smaldone MC, Kosarek CD, Fang JE, Ynalvez LA, Kim SP, Hoffman KE , Giordano SH, Chapin BF. Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data. Cancer 123(9):1617-1624, 2017. e-Pub 2017. PMID: 28099688.
100. Lang MF, Tyson MD, Alvarez JR, Koyama T, Hoffman KE , Resnick MJ, Cooperberg MR, Wu XC, Chen V, Paddock LE, Hamilton AS, Hashibe M, Goodman M, Greenfield S, Kaplan SH, Stroup A, Penson DF, Barocas DA. The Influence of Psychosocial Constructs on the Adherence to Active Surveillance for Localized Prostate Cancer in a Prospective, Population-based Cohort. Urology 103:173-178, 2017. e-Pub 2017. PMID: 28189554.
101. Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE , Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Ann Oncol 28(5):1098-1104, 2017. PMID: 28453693.
102. Holliday EB, Kuban DA, Levy LB, Bolukbasi Y, Master P, Choi S, Nguyen Q, McGuire SE, Mahmood U, Frank SJ, Hoffman KE. Select men benefit from androgen deprivation therapy delivered with salvage radiation therapy after prostatectomy. Prostate Cancer Prostatic Dis. e-Pub 2017. PMID: 28462945.
103. Reddy JP, Pettaway CA, Levy LB, Pagliaro LC, Tamboli P, Rao P, Jayaratna I, Hoffman KE . Factors associated with regional recurrence after lymph node dissection for penile squamous cell carcinoma. BJU Int 119(4):591-597, 2017. e-Pub 2016. PMID: 27753187.
104. Eifler JB, Alvarez J, Koyama T, Conwill RM, Ritch CR, Hoffman KE , Resnick MJ, Penson DF, Barocas DA, Collaborators. More judicious use of expectant management for localized prostate cancer over the past two decades. J Urol 197(3 Pt 1):614-620, 2017. e-Pub 2016. PMID: 27984110.
105. Moran MS, Zhao Y, Ma S, Kirova Y, Fourquet A, Chen P, Hoffman KE , Hunt K, Wong J, Halasz LM, Freedman G, Prosnitz R Jr, Yassa M, Nguyen DH, Hijal T, Haffty BG, Wai ES, Truong PT. Association of Radiotherapy Boost for Ductal Carcinoma In Situ With Local Control After Whole-Breast Radiotherapy. Journal of American Medical Association Oncology, 2017. e-Pub 2017. PMID: 28358936.
106. Barocas DA, Alvarez J, Resnick MJ, Koyama T, Hoffman KE , Tyson MD, Conwill R, McCollum D, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Penson DF. Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years. JAMA 317(11):1126-1140, 2017. PMID: 28324093.
107. Chen YW, Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Choueiri TK, Hoffman KE , Martin NE, Orio PF, Sweeney CJ, Feng FY, Trinh QD, Nguyen PL. Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy 15(6):695-700, 2016. e-Pub 2016. PMID: 27528590.
108. Stauder MC, Caudle AS, Allen PK, Shaitelman SF, Smith BD, Hoffman KE , Buchholz TA, Chavez-Macgregor M, Hunt KK, Meric-Bernstam F, Woodward WA. Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. Int J Radiat Oncol Biol Phys 96(3):637-44, 2016. e-Pub 2016. PMID: 27681760.
109. Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE , Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL. National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. Cancer 122(21):3371-3377, 2016. e-Pub 2016. PMID: 27434225.
110. Hoffman KE, Skinner H, Pugh TJ, Voong KR, Levy LB, Choi S, Frank SJ, Lee AK, Mahmood U, McGuire SE, Schlembach PJ, Du W, Johnson J, Kudchadker RJ, Kuban DA. Patient-Reported Urinary, Bowel and Sexual Function After Hypofractionated Intensity-Modulated Radiation Therapy for Prostate Cancer: Results from a Randomized Trial. Am J Clin Oncol. e-Pub 2016. PMID: 27635624.
111. Bian SX, Kuban DA, Levy LB, Oh J, Choi S, McGuire SE, Frank SJ, Mahmood U, Nguyen PL, Pugh TJ, Lee AK, Hoffman KE . The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer. Am J Clin Oncol 39(4):368-73, 2016. e-Pub 2014. PMID: 24732810.
112. Sohn W, Resnick MJ, Greenfield S, Kaplan SH, Phillips S, Koyama T, Goodman M, Hamilton AS, Hashibe M, Hoffman KE, Paddock LE, Stroup AM, Wu XC, Penson DF, Barocas DA. Impact of Adherence to Quality Measures for Localized Prostate Cancer on Patient-Reported Health-Related Quality of Life Outcomes, Patient Satisfaction, and Treatment-Related Complications. Med Care 54(8):738-44, 2016. e-Pub 2016. PMID: 27219634.
113. Pugh TJ, Choi S, Nogueras-Gonzalaez GM, Nguyen QN, Mahmood U, Frank SJ, Mathai B, Zhu XR, Sahoo N, Gillin M, Kuban DA, Hoffman KE , McGuire SE, Lee AK. Proton Beam Therapy for Localized Prostate Cancer: Results from a Prospective Quality of Life Trial. International Journal of Particle Therapy 3(1):27-36. e-Pub 2016. PMID: 31772973.
114. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE , Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int 118(1):68-76, 2016. e-Pub 2015. PMID: 26059275.
115. Mahal BA, Muralidhar V, Chen YW, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Trinh QD, Nguyen PL. Gleason 5 + 3 = 8 Prostate Cancer: Much More like Gleason 9?. BJU Int 118(1):95-101, 2016. e-Pub 2015. PMID: 26207642.
116. Benedict SH, Hoffman K, Martel MK, Abernethy AP, Asher AL, Capala J, Chen RC, Chera B, Couch J, Deye J, Efstathiou JA, Ford E, Fraass BA, Gabriel PE, Huser V, Kavanagh BD, Khuntia D, Marks LB, Mayo C, McNutt T, Miller RS, Moore KL, Prior F, Roelofs E, Rosenstein BS, Sloan J, Theriault A, Vikram B. Overview of the American Society for Radiation Oncology-National Institutes of Health-American Association of Physicists in Medicine Workshop 2015: Exploring Opportunities for Radiation Oncology in the Era of Big Data. Int J Radiat Oncol Biol Phys 95(3):873-9, 2016. PMID: 27302503.
117. Ho V, Ku-Goto MH, Zhao H, Hoffman KE, Smith BD, Giordano SH. Regional differences in recommended cancer treatment for the elderly. BMC Health Serv Res 16:262, 2016. e-Pub 2016. PMID: 27417075.
118. Shirvani SM, Jiang J, Likhacheva A, Hoffman KE , Shaitelman SF, Caudle A, Buchholz TA, Giordano SH, Smith BD. Trends in local therapy utilization and cost for early-stage breast cancer in older women: Implications for payment and policy reform. Int J Radiat Oncol Biol Phys 95(2):605-16, 2016. e-Pub 2016. PMID: 27034179.
119. Dinh KT, Reznor G, Muralidhar V, Mahal BA, Nezolosky MD, Choueiri TK, Hoffman KE , Hu JC, Sweeney CJ, Trinh QD, Nguyen PL. Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. J Clin Oncol 34(16):1905-12, 2016. e-Pub 2016. PMID: 27069075.
120. Goodman KA, Patton CE, Fisher GA, Hoffe SE, Haddock MG, Parikh PJ, Kim J, Baxter NN, Czito BG, Hong TS, Herman JM, Crane CH, Hoffman KE. Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the RAND/UCLA Appropriateness Method. Pract Radiat Oncol 6(3):166-75, 2016. e-Pub 2015. PMID: 26922700.
121. Kalra S, Basourakos S, Abouassi A, Achim M, Volk RJ, Hoffman KE, Davis JW, Kim J. The implications of ageing and life expectancy in prostate cancer treatment. Nat Rev Urol 13(5):289-95, 2016. e-Pub 2016. PMID: 27001016.
122. Ovalle V, Strom EA, Godby J, Shaitelman SF, Stauder MC, Amos RA, Kuerer HM, Woodward WA, Hoffman KE . Proton Partial-Breast Irradiation for Early-Stage Cancer: Is It Really So Costly?. Int J Radiat Oncol Biol Phys 95(1):49-51, 2016. PMID: 27084625.
123. Mahal BA, Chen YW, Efstathiou JA, Muralidhar V, Hoffman KE, Yu JB, Feng FY, Beard CJ, Martin NE, Orio PF, Nguyen PL. National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer 122(10):1505-12, 2016. e-Pub 2016. PMID: 26970022.
124. Williams SB, Huo J, Chamie K, Hu JC, Giordano SH, Hoffman KE , Dinney CPN, Kamat AM, Shih YT. Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer. Eur Urol Focus. e-Pub 2016. PMID: 28753760.
125. Muralidhar V, Catalano PJ, Reznor G, Mahal BA, Choueiri TK, Sweeney CJ, Martin NE, Beard CJ, Chen YW, Nezolosky MD, Hoffman KE, Feng FY, Trinh QD, Nguyen PL. Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. J Natl Compr Canc Netw 14(4):421-8, 2016. PMID: 27059190.
126. Kalra S, Basourakos S, Abouassi A, Achim M, Volk R, Hoffman K, Davis J, Kim J. The implications of aging and life expectancy in prostate cancer treatment. Nature Reviews Urology. e-Pub 2016.
127. Chen YW, Mahal BA, Muralidhar V, Nezolosky M, Beard CJ, Den RB, Feng FY, Hoffman KE, Martin NE, Orio PF, Nguyen PL. Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 94(4):683-90, 2016. e-Pub 2015. PMID: 26972640.
128. O'Neil B, Koyama T, Alvarez J, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, Stanford JL, Stroup AM, Paddock LE, Wu XC, Stephenson RA, Resnick MJ, Barocas DA, Penson DF. The Comparative Harms of Open and Robotic Prostatectomy in Population-Based Samples. J Urol 195(2):321-9, 2016. e-Pub 2015. PMID: 26343985.
129. Muralidhar V, Xiang M, Orio PF, Martin NE, Beard CJ, Feng FY, Hoffman KE, Nguyen PL. Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. J Contemp Brachytherapy 8(1):1-6, 2016. e-Pub 2016. PMID: 26985191.
130. Koontz BF, Benda R, De Los Santos J, Hoffman KE, Huq MS, Morrell R, Sims A, Stevens S, Yu JB, Chen RC. U.S. Radiation Oncology Practice Patterns for Post-Treatment Survivor Care. Pract Radiat Oncol 6(1):50-6, 2016. e-Pub 2015. PMID: 26603597.
131. Bishop AJ, Ensor J, Moulder SL, Shaitelman SF, Edson MA, Whitman GJ, Bishnoi S, Hoffman KE , Stauder MC, Valero V, Buchholz TA, Ueno NT, Babiera G, Woodward WA. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer 121(24):4324-32, 2015. e-Pub 2015. PMID: 26348887.
132. Muralidhar V, Chen MH, Reznor G, Moran BJ, Braccioforte MH, Beard CJ, Feng FY, Hoffman KE , Choueiri TK, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. Int J Radiat Oncol Biol Phys 93(4):828-35, 2015. e-Pub 2015. PMID: 26530751.
133. Shaitelman SF, Schlembach PJ, Arzu I, Ballo M, Bloom ES, Buchholz D, Chronowski GM, Dvorak T, Grade E, Hoffman KE , Kelly P, Ludwig M, Perkins GH, Reed V, Shah S, Stauder MC, Strom EA, Tereffe W, Woodward WA, Ensor J, Baumann D, Thompson AM, Amaya D, Davis T, Guerra W, Hamblin L, Hortobagyi G, Hunt KK, Buchholz TA, Smith BD. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. JAMA Oncol 1(7):931-41, 2015. e-Pub 2015. PMID: 26247543.
134. Chen RC, Hoffman KE , Sher DJ, Showalter TN, Morrell R, Chen AB, Benda R, Nguyen PL, Movsas B, Hardenbergh P. Development of a standard survivorship care plan template for radiation oncologists. Practical Radiation Oncology 6(1):57-65, 2015. e-Pub 2015. PMID: 26778795.
135. Ziehr DR, Chen MH, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, Hyatt AS, Basaria SS, Beard CJ, Beckman JA, Choueiri TK, D'Amico AV, Hoffman KE , Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Association of Androgen Deprivation Therapy with Excess Cardiac-Specific Mortality in Men with Prostate Cancer. BJU Int 116(3):358-65, 2015. e-Pub 2014. PMID: 25124891.
136. Strom EA, Amos RA, Shaitelman SF, Kerr MD, Hoffman KE , Smith BD, Tereffe W, Stauder MC, Perkins GH, Amin MD, Wang X, Poenisch F, Ovalle V, Buchholz TA, Babiera G, Woodward WA. Proton partial breast irradiation in the supine position: treatment description and reproducibility of a multibeam technique. Pract Radiat Oncol 5(4):e283-90, 2015. e-Pub 2015. PMID: 25804105.
137. Muralidhar V, Dinh KT, Mahal BA, Ziehr DR, Chen YW, Viswanathan VB, Nezolosky MD, Choueiri TK, Hoffman KE , Hu JC, Sweeney CJ, Trinh QD, Nguyen PL. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urol Oncol 33(7):330.e19-25, 2015. e-Pub 2015. PMID: 25990612.
138. Holliday EB, Ahmed AA, Yoo SK, Jagsi R, Hoffman KE . Does Cancer Literature Reflect Multidisciplinary Practice? A Systematic Review of Oncology Studies in the Medical Literature Over a 20-Year Period. Int J Radiat Oncol Biol Phys 92(4):721-31, 2015. e-Pub 2015. PMID: 26104927.
139. Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Koyama T, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE , Hoffman RM, Kaplan SH, McCollum D, Paddock LE, Stanford JL, Stroup AM, Wu XC, Penson DF. The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research. Eur Urol 67(6):1019-25, 2015. e-Pub 2014. PMID: 25174325.
140. Mahal BA, Hoffman KE , Efstathiou JA, Nguyen PL. National Trends in the Recommendation of Radiotherapy After Prostatectomy for Prostate Cancer Before and After the Reporting of a Survival Benefit in March 2009. Clin Genitourin Cancer 13(3):e167-72, 2015. e-Pub 2014. PMID: 25554010.
141. Bishop AJ, Ensor J, Moulder SL, Shaitelman SF, Edson MA, Whitman GJ, Bishnoi S, Hoffman KE , Stauder MC, Valero V, Buchholz TA, Ueno NT, Babiera G, Woodward WA. Prognosis for Patients with Metastatic Breast Cancer Who Acheive "No Evidence-of-Disease" Status After Systematic or Local Therapy. Oncology (Williston Park)(29), 2015. PMID: 25930789.
142. Resnick MJ, Lacchetti C, Bergman J, Hauke RJ, Hoffman KE , Kungel TM, Morgans AK, Penson DF. Prostate Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol 33(9):1078-85, 2015. e-Pub 2015. PMID: 25667275.
143. Jagsi R, Bekelman JE, Chen A, Chen RC, Hoffman K , Shih YC, Smith BD, Yu JB. In reply to Rusthoven and Kavanagh. Int J Radiat Oncol Biol Phys 91(3):680-1, 2015. e-Pub 2015. PMID: 25680609.
144. Mahal BA, Inverso G, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hoffman KE , Hu JC, Beard CJ, D'Amico AV, Martin NE, Orio PF, Trinh QD, Nguyen PL. Incidence and Determinants of 1-Month Mortality after Cancer-Directed Surgery. Ann Oncol 26(2):399-406, 2015. e-Pub 2014. PMID: 25430935.
145. Thaker NG, Hoffman KE, Stauder MC, Shaitelman SF, Strom EA, Tereffe W, Smith BD, Perkins GH, Huo L, Munsell MF, Pusztai L, Buchholz TA, Woodward WA. The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer. Springerplus 4:36, 2015. e-Pub 2015. PMID: 25674496.
146. Holliday EB, Yang G, Jagsi R, Hoffman KE , Bennett KE, Grace C, Zietman AL. Fate of manuscripts rejected from the Red Journal. Int J Radiat Oncol Biol Phys 91(1):3-10, 2015. PMID: 25835616.
147. Mahmood U, Levy LB, Nguyen PL, Lee AK, Kuban DA, Hoffman KE . Current Clinical Presentation and Treatment of Localized Prostate Cancer in the United States. J Urol 192(6):1650-6, 2014. e-Pub 2014. PMID: 24931803.
148. Mahal BA , Hoffman KE , Efstathiou JA, Nguyen PL. National Trends in the Recommendation of Post-Prostatectomy Radiotherapy for Prostate Cancer Before and After the Reporting of a Survival Benefit in March 2009. Clinical Genitourinary Cancer, 2014. e-Pub 2014.
149. Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Hoffman KE, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL. Racial Disparities in Prostate Cancer--Specific Mortality in Men With Low-Risk Prostate Cancer. Clin Genitourin Cancer 12(5):e189-95, 2014. e-Pub 2014. PMID: 24861952.
150. Walker GV, Grant SR, Guadagnolo BA, Hoffman KE, Smith BD, Koshy M, Allen PK, Mahmood U. Disparities in Stage at Diagnosis, Treatment, and Survival in Nonelderly Adult Patients With Cancer According to Insurance Status. J Clin Oncol 32(28):3118-25, 2014. e-Pub 2014. PMID: 25092774.
151. Jagsi R, Bekelman JE, Chen A, Chen RC, Hoffman K , Shih YC, Smith BD, Yu JB. Considerations for Observational Research using Large Datasets in Radiation Oncology. Int J Radiat Oncol Biol Phys 90(1):11-24, 2014. PMID: 25195986.
152. Hoffman KE , Niu J, Shen Y, Jiang J, Davis JW, Kim J, Kuban DA, Perkins GH, Shah JB, Smith GL, Volk RJ, Buchholz TA, Giordano SH, Smith BD. Physician variation in management of low-risk prostate cancer; a population-based cohort study. JAMA Intern Med 174(9):1450-9, 2014. e-Pub 2014. PMID: 25023650.
153. Hoffman KE , Pugh SL, James JL, Scarantino C, Movsas B, Valicenti RK, Fortin A, Pollock J, Kim H, Brachman DG, Berk LB, Bruner DW, Kachnic LA. The impact of concurrent granulocyte-macrophage colony-stimulating factor on quality of life in head and neck cancer patients: results of the randomized, placebo-controlled Radiation Therapy Oncology Group 9901 trial. Qual Life Res 23(6):1841-58, 2014. e-Pub 2014. PMID: 24492945.
154. Dayyani F, Hoffman K , Eifel P, Guo C, Vikram R, Pagliaro LC, Pettaway C. Management of Advanced Primary Urethral Carcinomas. BJU Int 114(1):25-31, 2014. e-Pub 2014. PMID: 24447439.
155. Aizer AA, Falit B, Mendu ML, Chen MH, Choueiri TK, Hoffman KE , Hu JC, Martin NE, Trinh QD, Alexander BM, Nguyen PL. Cancer-Specific Outcomes Among Young Adults Without Health Insurance. J Clin Oncol 32(19):2025-2030, 2014. e-Pub 2014. PMID: 24888800.
156. Madsen LT, Kuban DA, Choi S, Davis JW, Kim J, Lee AK, Domain D, Levy L, Pisters LL, Pettaway CA, Ward JF, Logothetis C, Hoffman KE . Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic. J Natl Compr Canc Netw 12(7):993-8, 2014. PMID: 24994920.
157. Aizer AA, Chen MH, Parekh A, Choueiri TK, Hoffman KE , Kim SP, Martin NE, Hu JC, Trinh QD, Nguyen PL. Refusal of Curative Radiation Therapy and Surgery Among Patients With Cancer. Int J Radiat Oncol Biol Phys. e-Pub 2014. PMID: 24803037.
158. Aizer AA, Wilhite TJ, Chen MH, Graham PL, Choueiri TK, Hoffman KE , Martin NE, Trinh QD, Hu JC, Nguyen PL. Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer 120(10):1532-9, 2014. e-Pub 2014. PMID: 24863392.
159. Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Chen VW, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE , Kaplan SH, Paddock LE, Stroup AM, Wu XC, Koyama T, Penson DF. Contemporary Prevalence of Pre-Treatment Urinary, Sexual, Hormonal, and Bowel Dysfunction: Defining the Population At-Risk for Harms of Prostate Cancer Treatment. Cancer 120(8):1263-71, 2014. e-Pub 2014. PMID: 24510400.
160. Hoffman KE, Voong KR, Pugh TJ, Skinner H, Levy LB, Takiar V, Choi S, Du W, Frank SJ, Johnson J, Kanke J, Kudchadker RJ, Lee AK, Mahmood U, McGuire SE, Kuban DA. Risk of Late Toxicity in Men Receiving Dose-Escalated Hypofractionated Intensity Modulated Prostate Radiation Therapy: Results From a Randomized Trial. Int J Radiat Oncol Biol Phys 88(5):1074-84, 2014. PMID: 24661661.
161. Wang J, Kudchadker Rajat, Choi S, Pettaway CA, Choi H, Hobbs BD, Occena MC, McGuire SE, Pugh TJ, Hoffman KE ,Mahmood U, Kuban DA. Local recurrence map to guide target volume delineation after radical prostatectomy. Practical Radiation Oncology, 2014. e-Pub 2014.
162. Mahmood U, Pugh T, Frank S, Levy L, Walker G, Haque W, Koshy M, Graber W, Swanson D, Hoffman K , Kuban D, Lee A. Declining use of brachytherapy for the treatment of prostate cancer. Brachytherapy 13(2):157-62, 2014. e-Pub 2013. PMID: 24050892.
163. MacDermed DM, Houtman KM, Thang SH, Allen PK, Caudle AS, Gainer SM, Hunt KK, Perkins GH, Shaitelman SF, Smith BD, Strom EA, Tereffe W, Woodward WA, Buchholz TA, Hoffman KE . Therapeutic radiation dose delivered to the low axilla during whole breast radiation therapy in the prone position: Implications for targeting the undissected axilla. Pract Radiat Oncol 4(2):116-22, 2014. e-Pub 2013. PMID: 24890352.
164. Smith GL, Jiang J, Buchholz TA, Xu Y, Hoffman KE , Giordano SH, Hunt KK, Smith BD. Benefit of adjuvant brachytherapy versus external beam radiation for early breast cancer: Impact of patient stratification on breast preservation. Int J Radiat Oncol Biol Phys 88(2):274-84, 2014. e-Pub 2013. PMID: 24268788.
165. Du W, Cho SH, Zhang X, Hoffman KE , Kudchadker RJ. Quantification of beam complexity in intensity-modulated radiation therapy treatment plans. Med Phys 41(2):021716, 2014. PMID: 24506607.
166. Caudle AS, Yi M, Hoffman KE , Mittendorf EA, Babiera GV, Hwang RF, Meric-Bernstam F, Sahin AA, Hunt KK. Impact of Identification of Internal Mammary Sentinel Lymph Node Metastasis in Breast Cancer Patients. Ann Surg Oncol 21(1):60-5, 2014. e-Pub 2013. PMID: 24046126.
167. Takiar V, Akay CL, Stauder MC, Tereffe W, Alvarez RH, Hoffman KE , Perkins GH, Strom EA, Buchholz TA, Ueno NT, Babiera G, Woodward WA. Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. Springerplus 3:166, 2014. e-Pub 2014. PMID: 24711988.
168. Aizer AA, Chen MH, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, Graham PL, Choueiri TK, Hoffman KE, Martin NE, Hu JC, Nguyen PL. Marital Status and Survival in Patients With Cancer. J Clin Oncol 31(31):3869-76, 2013. e-Pub 2013. PMID: 24062405.
169. Weksberg DC, Allen PK, Hoffman KE, Litton JK, Strom EA, Shah RR, Kuerer HM, Hunt KK, Buchholz TA, Mittendorf EA. Outcomes and Predictive Factors for Salvage Therapy After Local-Regional Recurrence Following Neoadjuvant Chemotherapy and Breast Conserving Therapy. Ann Surg Oncol 20(11):3430-7, 2013. e-Pub 2013. PMID: 23720073.
170. Pugh TJ, Munsell MF, Choi S, Nguyen QN, Mathai B, Zhu XR, Sahoo N, Gillin M, Johnson JL, Amos RA, Dong L, Mahmood U, Kuban DA, Frank SJ, Hoffman KE , McGuire SE, Lee AK. Quality of Life and Toxicity From Passively Scattered and Spot-Scanning Proton Beam Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. e-Pub 2013. PMID: 24139077.
171. Parekh A, Chen MH, D'Amico AV, Dosoretz DE, Ross R, Salenius S, Graham PL, Beckman JA, Beard CJ, Choueiri TK, Ennis RD, Hoffman KE, Hu JC, Ma J, Martin NE, Nguyen PL. Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. Brachytherapy 12(5):415-21, 2013. e-Pub 2013. PMID: 23651926.
172. Aizer A, Chen MH, McCarthy E, Mendu M, Koo S, Wilhite T, Graham P, Choueiri T, Hoffman KE, Martin N, Hu J, Nguyen P. Martial Status and Survival in Patients with Cancer. J Clin Oncol, 2013. PMID: 24062405.
173. Nguyen QN, Levy LB, Lee AK, Choi SS, Frank SJ, Pugh TJ, McGuire S, Hoffman K, Kuban DA. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer 119(18):3265-71, 2013. e-Pub 2013. PMID: 23798338.
174. Beard CJ, Travis LB, Chen MH, Arvold ND, Nguyen PL, Martin NE, Kuban DA, Ng AK, Hoffman KE. Outcomes in stage I testicular seminoma: A population-based study of 9193 patients. Cancer 119(15):2771-7, 2013. e-Pub 2013. PMID: 23633409.
175. Cerne JZ, McGuire SE, Grant SR, Munsell MF, Lee AK, Kudchadker RJ, Choi SL, Mahmood U, Hoffman KE, Pugh TJ, Frank SJ, Kuban DA. Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients. Prostate Cancer Prostatic Dis. e-Pub 2013. PMID: 23939133.
176. Barocas DA, Chen V, Cooperberg M, Goodman M, Graff J, Greenfield S, Hamilton A, Hoffman KE, Kaplan S, Koyama T, Morgans A, Phillips S, Resnick M, Stroup A, Wu XC, Penson DF. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: The CEASAR study. Journal of Comparative Effectiveness Research 2(4):445-460, 2013. PMID: 24236685.
177. Hoffman KE, Kuban DA. Lymph node-positive prostate cancer: the benefit of local therapy. Oncology (Williston Park) 27(7):655, 660-1, 2013. PMID: 23977760.
178. Pugh TJ, Frank SJ, Achim M, Kuban DA, Lee AK, Hoffman KE, McGuire SE, Swanson DA, Kudchadker R, Davis JW. Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: Implications for prostate brachytherapy. Brachytherapy 12(3):204-9, 2013. e-Pub 2012. PMID: 22673704.
179. Efstathiou JA, Nassif DS, McNutt TR, Bogardus CB, Bosch W, Carlin J, Chen RC, Chou H, Eggert D, Fraass BA, Goldwein J, Hoffman KE, Hotz K, Hunt M, Kessler M, Lawton CA, Mayo C, Michalski JM, Mutic S, Potters L, Rose CM, Sandler HM, Sharp G, Tomé W, Tran PT, Wall T, Zietman AL, Gabriel PE, Bekelman JE. Practice-Based Evidence to Evidence-Based Practice: Building the National Radiation Oncology Registry. J Oncol Pract 9(3):e90-e95, 2013. PMID: 23942508.
180. Wang X, Zhang X, Li X, Amos RA, Shaitelman SF, Hoffman K, Howell R, Salehpour M, Zhang SX, Sun TL, Smith B, Tereffe W, Perkins GH, Buchholz TA, Strom EA, Woodward WA. Accelerated Partial-Breast Irradiation Using Intensity-Modulated Proton Radiotherapy: Do Uncertainties Outweigh Potential Benefits?. Br J Radiol. e-Pub 2013. PMID: 23728947.
181. Bian SX, Kuban DA, Levy LB, Oh J, Castle KO, Pugh TJ, Choi S, McGuire SE, Nguyen QN, Frank SJ, Nguyen PL, Lee AK, Hoffman KE. Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol, Indian Excerpted Edition 4(2), 2013.
182. Hoffman KE, Niu J, Giordano SH, Ho V, Smith BD. Prostate Cancer Treatment Patterns in the State of Texas, 2004-2007. TPHA 65(2):36-42, 2013.
183. Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Pugh TJ, McGuire SE, Kuban DA. Is Androgen Deprivation Therapy Necessary in All Intermediate Risk Prostate Cancer Patients Treated in the Dose Escalation Era?. Int J Radiat Oncol Biol Phys 85(3):693-9, 2013. e-Pub 2012. PMID: 22836052.
184. Mittendorf EA, Buchholz TA, Tucker SL, Meric-Bernstam F, Kuerer HM, Gonzalez-Angulo AM, Bedrosian I, Babiera GV, Hoffman K, Yi M, Ross MI, Hortobagyi GN, Hunt KK. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Ann Surg 257(2):173-9, 2013. PMID: 23291658.
185. McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA. PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era. Int J Radiat Oncol Biol Phys 85(1):e39-46, 2013. e-Pub 2012. PMID: 23102837.
186. Parekh A, Chen MH, Hoffman KE, Choueiri TK, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K, Graham PL, D'Amico AV, Nguyen PL. Reduced Penile Size and Treatment Regret in Men With Recurrent Prostate Cancer After Surgery, Radiotherapy Plus Androgen Deprivation, or Radiotherapy Alone. Urology 81(1):130-5, 2013. PMID: 23273077.
187. Arvold ND, Catalano PJ, Sweeney CJ, Hoffman KE, Nguyen PL, Balboni TA, Fosså SD, Travis LB, Beard CJ. Barriers to the Implementation of Surveillance for Stage I Testicular Seminoma. Int J Radiat Oncol Biol Phys 84(2):383-9, 2012. e-Pub 2012. PMID: 22349043.
188. Holmes JA, Wang AZ, Hoffman KE, Hendrix LH, Rosenman JG, Carpenter WR, Godley PA, Chen RC. Is Primary Prostate Cancer Treatment Influenced by Likelihood of Extraprostatic Disease? A Surveillance, Epidemiology and End Results Patterns of Care Study. Int J Radiat Oncol Biol Phys 84(1):88-94, 2012. e-Pub 2012. PMID: 22300560.
189. Bian SX, Kuban DA, Levy LB, Oh J, Castle KO, Pugh TJ, Choi S, McGuire SE, Nguyen QN, Frank SJ, Nguyen PL, Lee AK, Hoffman KE. Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol 23(9):2346-52, 2012. e-Pub 2012. PMID: 22357249.
190. Jhaveri PM, Sun Z, Ballas L, Followill DS, Hoffman KE, Jiang J, Smith BD. Emergence of Integrated Urology-Radiation Oncology Practices in the State of Texas. Int J Radiat Oncol Biol Phys 84(1):15-9, 2012. e-Pub 2012. PMID: 22789491.
191. Albert JM, Liu DD, Shen Y, Pan IW, Shih YC, Hoffman KE, Buchholz TA, Giordano SH, Smith BD. Nomogram to Predict the Benefit of Radiation for Older Patients With Breast Cancer Treated With Conservative Surgery. J Clin Oncol 30(23):2837-43, 2012. e-Pub 2012. PMID: 22734034.
192. Nguyen PL, Chen MH, Hoffman KE, Chen RC, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K, D'Amico AV. Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. BJU Int 110(2):201-205, 2012. e-Pub 2011. PMID: 22085233.
193. Pinnix C, Perkins GH, Strom EA, Tereffe W, Woodward W, Oh JL, Arriaga L, Munsell MF, Kelly P, Hoffman KE, Smith BD, Buchholz TA, Yu TK. Topical Hyaluronic Acid vs. Standard of Care for the Prevention of Radiation Dermatitis After Adjuvant Radiotherapy for Breast Cancer: Single-Blind Randomized Phase III Clinical Trial. Int J Radiat Oncol Biol Phys 83(4):1089-94, 2012. e-Pub 2011. PMID: 22172912.
194. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Prostate cancer-specific mortality after definitive radiation therapy: Who dies of disease?. Eur J Cancer 48(11):1664-71, 2012. e-Pub 2012. PMID: 22336663.
195. Caudle AS, Hunt KK, Mittendorf EA, Tucker SL, Hoffman KE, Gainer SM, Lucci A, Kuerer HM, Meric-Bernstam F, Babiera G, Sahin AA, Shah RR. American College of Surgeons Oncology Group (ACOSOG) Z0011: Impact on Surgeon Practice Patterns. Am Surg Oncol, 2012. e-Pub 2012.
196. Sharp HJ, Swanson DA, Pugh TJ, Zhang M, Phan J, Kudchadker R, Bruno TL, Kuban DA, Lee AK, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Frank SJ. Screening colonoscopy before prostate cancer treatment can detect colorectal cancers in asymptomatic patients and reduce the rate of complications after brachytherapy. Pract Radiat Oncol 2(3):e7-e13, 2012. e-Pub 2012. PMID: 24674130.
197. Hoffman KE, Mittendorf EA, Buchholz TA. Optimising radiation treatment decisions for patients who receive neoadjuvant chemotherapy and mastectomy. Lancet Oncol 13(6):e270-6, 2012. PMID: 22652235.
198. Akay CL, Meric-Bernstam F, Hunt KK, Grubbs EG, Bedrosian I, Tucker SL, Kuerer HM, Hoffman KE, Babiera GV, Strom EA, Buchholz TA, Mittendorf EA. Evaluation of the MD Anderson prognostic index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol 19(3):901-7, 2012. e-Pub 2011. PMID: 21861223.
199. Nguyen PL, Chen MH, Beckman JA, Beard CJ, Martin NE, Choueiri TK, Hu JC, Hoffman KE, Dosoretz DE, Moran BJ, Salenius SA, Braccioforte MH, Kantoff PW, D'Amico AV, Ennis RD. Influence of androgen deprivation therapy (ADT) on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure (CHF) or myocardial infarction (MI). Int J Radiat Oncol Biol Phys 82(4):1411-6, 2012. e-Pub 2011. PMID: 21708431.
200. Wang X, Pan T, Pinnix C, Zhang SX, Salehpour M, Sun TL, Gladish G, Strom EA, Perkins GH, Tereffe W, Woodward W, Hoffman KE, Buchholz TA, Yu TK. Cardiac motion during deep-inspiration breath-hold: implications for breast cancer radiotherapy. Int J Radiat Oncol Biol Phys 82(2):708-14, 2012. e-Pub 2011. PMID: 21444161.
201. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J 18(1):1-8, 2012. PMID: 22290249.
202. Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res 14(3):R83, 2012. e-Pub 2012. PMID: 22621334.
203. Hoffman KE, Neville BA, Mamon HJ, Kachnic LA, Katz MS, Earle CC, Punglia RS. Adjuvant therapy for elderly patients with resected gastric adenocarcinoma: population-based practices and treatment effectiveness. Cancer 118(1):248-57, 2012. e-Pub 2011. PMID: 21692071.
204. Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306(21):2359-66, 2011. PMID: 22147380.
205. Shirvani SM, Pan IW, Buchholz TA, Shih YC, Hoffman KE, Giordano SH, Smith BD. Impact of evidence-based clinical guidelines on the adoption of postmastectomy radiation in older women. Cancer 117(20):4595-605, 2011. e-Pub 2011. PMID: 21710653.
206. Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EA. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol 18(9):2407-12, 2011. e-Pub 2011. PMID: 21327455.
207. Wang X, Amos RA, Zhang X, Taddei PJ, Woodward WA, Hoffman KE, Yu TK, Tereffe W, Oh J, Perkins GH, Salehpour M, Zhang SX, Sun TL, Gillin M, Buchholz TA, Strom EA. External-beam accelerated partial breast irradiation using multiple proton beam configurations. Int J Radiat Oncol Biol Phys 80(5):1464-72, 2011. e-Pub 2010. PMID: 20708848.
208. Mak RH, McCarthy EP, Das P, Hong TS, Mamon HJ, Hoffman KE. Adoption of preoperative radiation therapy for rectal cancer from 2000 to 2006: a surveillance epidemiology and end results patterns of care study. Int J Radiat Oncol Biol Phys 80(4):978-84, 2011. e-Pub 2010. PMID: 20961695.
209. Albert JM, Buzdar AU, Guzman R, Allen PK, Strom EA, Perkins GH, Woodward WA, Hoffman KE, Tereffe W, Hunt KK, Buchholz TA, Oh JL. Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control. Breast Cancer Res Treat 128(2):421-7, 2011. e-Pub 2011. PMID: 21553292.
210. Nguyen PL, Chen MH, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Beard CJ, Dosoretz DE, Moran BJ, Katin MJ, Braccioforte MH, Ross R, Salenius SA, Kantoff PW, D'Amico AV. Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. Int J Radiat Oncol Biol Phys 79(5):1318-22, 2011. e-Pub 2010. PMID: 20605366.
211. Nguyen PL, Gu X, Lipsitz SR, Choueiri TK, Choi WW, Lei Y, Hoffman KE, Hu JC. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 29(12):1517-24, 2011. e-Pub 2011. PMID: 21402604.
212. Hoffman KE, Nguyen PL, Chen MH, Chen RC, Choueiri TK, Hu JC, Kuban DA, D'Amico AV. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol 185(1):116-20, 2011. e-Pub 2010. PMID: 21074194.
213. Nguyen PL, Chen RC, Hoffman KE, Trofimov A, Efstathiou JA, Coen JJ, Shipley WU, Zietman AL, Talcott JA. Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial. Int J Radiat Oncol Biol Phys 78(4):1081-5, 2010. e-Pub 2010. PMID: 20207497.
214. Ahove DA, Hoffman KE, Hu JC, Choueiri TK, D'Amico AV, Nguyen PL. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence? Implications for a risk-adapted follow-up strategy. Urology 76(5):1201-5, 2010. e-Pub 2010. PMID: 20709376.
215. Walker GV, Smith GL, Perkins GH, Oh JL, Woodward W, Yu TK, Hunt KK, Hoffman K, Strom EA, Buchholz TA. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer 116(17):4000-6, 2010. PMID: 20564117.
216. Hoffman KE, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin MJ, Ross R, D'Amico AV. Prostate-cancer specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer. Cancer 116(11):2590-5, 2010. e-Pub 2010. PMID: 20310055.
217. Hoffman KE, Nguyen PL, Ng AK, D'Amico AV. Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy. J Urol 183(5):1798-802, 2010. e-Pub 2010. PMID: 20299039.
218. Nguyen PL, Chen MH, Beard CJ, Suh WW, Choueiri TK, Efstathiou JA, Hoffman KE, Loffredo M, Kantoff PW, D'Amico AV. Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. Cancer 116(3):610-5, 2010. e-Pub 2009. PMID: 19957321.
219. Hoffman KE, Yock TI. Radiation therapy for pediatric central nervous system tumors. J Child Neurol 24(11):1387-96, 2009. PMID: 19841427.
220. Hoffman KE, McCarthy EP, Recklitis CJ, Ng AK. Psychological distress in long-term survivors of adult-onset cancer: results from a national survey. Arch Intern Med 169(14):1274-81, 2009. PMID: 19636028.
221. Hong SH, Briggs J, Newman R, Hoffman K, Mendoza A, LeRoith D, Helman L, Yakar S, Khanna C. Murine osteosarcoma primary tumor growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor I. Int J Cancer 124(9):2042-9, 2009. PMID: 19132750.
222. Nguyen PL, Chen MH, Hoffman KE, Katz MS, D'Amico AV. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys 74(1):104-9. e-Pub 2009. PMID: 19286330.
223. Hoffman KE, Chen MH, Punglia RS, Beard CJ, D'Amico AV. Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma. J Clin Oncol 26(24):3937-42, 2008. PMID: 18711182.
224. Hoffman KE, Hong TS, Zietman AL, Russell AH. External beam radiation treatment for rectal cancer is associated with a decrease in subsequent prostate cancer diagnosis. Cancer 112(4):943-9, 2008. PMID: 18098220.
225. Hoffman KE, Derdak J, Bernstein D, Reynolds JC, Avila NA, Gerber L, Steinberg SM, Chrousos G, Mackall CL, Mansky PJ. Metabolic syndrome traits in long-term survivors of pediatric sarcoma. Pediatr Blood Cancer 50(2):341-6, 2008. PMID: 17918262.
226. Hoffman KE, Horowitz NS, Russell AH. Healing of vulvo-vaginal radionecrosis following revascularization. Gynecol Oncol 106(1):262-4, 2007. PMID: 17507081.
227. Mansky P, Arai A, Stratton P, Bernstein D, Long L, Reynolds J, Chen D, Steinberg SM, Lavende N, Hoffman K, Nathan PC, Parks R, Augustine E, Chaudhry U, Derdak J, Wiener L, Gerber L, Mackall C. Treatment late effects in long-term survivors of pediatric sarcoma. Pediatr Blood Cancer 48(2):192-9, 2007. PMID: 16642490.
228. Gerber LH, Hoffman K, Chaudhry U, Augustine E, Parks R, Bernard M, Mackall C, Steinberg S, Mansky P. Functional outcomes and life satisfaction in long-term survivors of pediatric sarcomas. Arch Phys Med Rehabil 87(12):1611-7, 2006. PMID: 17141641.
229. Rowe-Taitt CA, Hazzard JW, Hoffman KE, Cras JJ, Golden JP, Ligler FS. Simultaneous detection of six biohazardous agents using a planar waveguide array biosensor. Biosens Bioelectron 15(11-12):579-89, 2000. PMID: 11213218.
230. Rowe-Taitt CA, Golden JP, Feldstein MJ, Cras JJ, Hoffman KE, Ligler FS. Array biosensor for detection of biohazards. Biosens Bioelectron 14(10-11):785-94, 2000. PMID: 10945453.
231. Bart JC, Judd LL, Hoffman KE, Wilkins AM, Kusterbeck AW. Application of a portable immunosensor to detect the explosives TNT and RDX in groundwater samples. Environmental Science Technology 31(5):1505-1511, 1997.
232. Wallis CJD, Huang LC, Zhao Z, Penson DF, Koyama T, Conwill R, Tallman JE, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Barocas DA, Hoffman KE* . Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: an assessment of the CEASAR cohort. Seminars in Urologic Oncology.
233. De BS, Lowenstein LM, Corrigan KL, Andring LM, Kuban DA, Cantor S, Volk R, Hoffman K* . Patients’ Preferences for Androgen Deprivation Therapy in the Treatment of Intermediate Risk Prostate Cancer.

Invited Articles

1. Hoffman KE. Wait and Hurry Up: Radiation Therapy for Prostate Cancer During the COVID-19 Pandemic. Int J Radiat Oncol Biol Phys 108(2):340, 2020. PMID: 32890505.
2. Bian SX, Hoffman KE. Management of Prostate Cancer in Elderly Men. Semin Radiat Oncol 23(3):198-205, 2013. PMID: 23763886.
3. Pugh TJ, Nguyen BN, Kanke JE, Johnson JL, Hoffman KE. Radiation Therapy Modalities in Prostate Cancer. J Natl Compr Canc Netw 11(4):414-21, 2013. PMID: 23584344.
4. Hoffman KE, Kuban DA. Commentary on Lymph-node Positive Prostate Cancer: The Benefit of Local Therapy. Oncology 27(7), 2013.
5. Hoffman KE. Management of Older Men with Clinically Localized Prostate Cancer: The Significance of Advanced Age and Comorbidity. Semin Radiat Oncol 22(4):284-94, 2012. PMID: 22985811.
6. Nguyen PL, Hoffman KE. Adjuvant vs. Salvage Radiation for pT3 or Margin Positive Prostate Cancer. AUA News 16(10):18-20, 2011.
7. Hoffman KE, Nguyen PL. The Debate over Prostate Cancer Screening Guidelines. Virtual Mentor 13(1):10-15, 2011. e-Pub 2011. PMID: 23121809.
8. Hoffman KE, Buchholz TA. How Improved Local-Regional Therapy Impacts Survival. Current Breast Cancer Reports 2(2):83-89. e-Pub 2010.

Editorials

1. Hoffman KE, Whitman GJ. Commentary on: Screening Breast MR Imaging in Women with a History of Chest Irradiation. Breast Diseases: A Year Book Quarterly 23(2), 2012.
2. Hoffman KE. Estimating Recurrences Prevented From Using Trastuzumab in HER-2/neu-Positive Adjuvant Breast Cancer in the United States. Breast Diseases: A Year Book Quarterly 22(3):297, 2011.
3. Hoffman KE. Commentary on: Long-Term Survival Among Patients with Hodgkin's Lymphoma who Developed Breast Cancer. Breast Diseases: A Year Book Quarterly 22(4):364-365, 2011.
4. Hoffman KE. Commentary on: Transitioning to Breast Cancer Survivorship: Perspectives of Patients, Cancer Specialists, and Primary Care Providers. Breast Diseases: A Year Book Quarterly 21(2):125-126, 2010.
5. Hoffman KE, Harris JR. Commentary on: Prognostic value of triple-negative phenotype at the time of locally recurrent conservatively treated breast cancer. Breast Diseases: A Year Book Quarterly 20(2):172-174, 2009.

Abstracts

1. Shaitelman SF, Gandhi A, DeSnyder S, Smith GL, Lin R, Barcenas C, Stauder MC, Hoffman KE, Strom EA, Ferguson S, Smith BD, Woodward BS, Perkins GH, Mitchell MP, Goodman CR, Aldrich M, Travis M, Lilly S, Bedrosian I. Prospective, Longitudinal Assessment of Lymphedema-related Quality of Life for Locally Advanced Breast Cancer Patients: A Foundation for Needed Elements in a Lymphedema Screening Program. American Radium Society 2022 Annual Meeting, 2022.
2. Singh P, Hoffman,K , Smith B, Clemens M, Ehlers R, Chu C, Adelman D, Villa M, Kuerer H, Schaverien M. A prospective clinical trial of immediate breast reconstruction following pre-mastectomy radiotherapy for operable breast cancer. Annals of Surgical Oncology 29(SUPPL 1):39-40, 2022.
3. Hoffman KE. ARS Scientific Program Committee Call, 2022.
4. Koontz BF, Hoffman KE, Halabi S, Healy P, Anand M, George DJ, Harrison MR, Zhang T, Berry WR, Corn PG, Lee WR, Armstrong, AJ. Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 109(5):1271-1278, 2021.
5. Dinh TKT, Mitin T, Bagshaw HP, Hoffman KE, Hwang C, Karnes RJ, Kishan AU, Liauw SL, Lloyd S, Potters L, Showalter TN, Taira AV, Vapiwala N, Zaorsky NG, D'Amico AV, Nguyen PL, Davis BJ. Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node -Negative Muscle Invasive Bladder Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 109(4):953-963, 2021.
6. Pasalic D, Barocas DA, Huang LC, Zhao ZG, Koyama T, Tang C, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup AM, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman KE. Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer. Cancer 127(11):1912-1925, 2021.
7. Dinh TK, Mitin T, Hoffman K, Hwang C, Karnes RJ, Kishan A, Liauw S, Lloyd S, Potters L, Showalter T, Taira A, Vapiwala N, Zaorsky N, D'Amico A, Nguyen P, Davis B. Towards Evidence Based Practice: The American Radium Society (ARS) and American College of Radiology (ACR) Appropriate Use Guidelines on Radiation Therapy for Muscle-Invasive Bladder Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 108(2):E34-E35, 2020.
8. Kim M, Abu-Gheida I, Bathala T, Maldonado JA, Khan M, Anscher MS, Frank SJ, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Kuban DA, Aparicio A, Chapin B, Tang C. Comparisons of Treatment Outcomes and Patterns of Lymph Node Involvement in T4 Prostate Cancer Patients. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 108(3):E912, 2020.
9. Camacho B, Johnston D, Rhodes B, Doughtie K, Fleming GG, Pham S, Todd SE, Ghafar R, Koong AC, Mitchell MP, Hoffman KE, Woodward WA. Specialized Navigation in a Breast Radiotherapy Practice Increases Clinic Capacity. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 108(3):E202-E203, 2020.
10. Boyce-Fappiano D, Bathala TK, Ye R, Pasalic D, Gjyshi O, Pezzi TA, Noticewala SS, McGinnis GJ, Maroongroge S, Kuban DA, Nguyen QN, McGuire SE, Hoffman KE, Choi S, Tang C, Kudchadker RJ, Frank SJ. Predictors of urinary toxicity with MRI-assisted radiosurgery for low- dose-rate prostate brachytherapy. BRACHYTHERAPY 19(5):574-583, 2020.
11. Luckenbaugh A, Wittmann D, Zhao ZG, Koyama T, Huang LC, Laviana A, Wallis C, Hoffman K, Penson D, Barocas D. ASSOCIATION BETWEEN TREATMENT FOR LOCALIZED PROSTATE CANCER AND MENTAL HEALTH OUTCOMES. JOURNAL OF UROLOGY 203(4):E1031-E1032, 2020.
12. Joyce DD, Luckenbaugh AN, Huelster HL, Zhao ZH, Hoffman KE, Huang LC, Koyama T, Conwill R, Penson DF, Barocas DA. Recovery Of Sexual Function In Men Treated With Androgen Deprivation Therapy For Localized Prostate Cancer. JOURNAL OF UROLOGY 203(4):E782-E783, 2020.
13. Huelster H, Laviana A, Joyce D, Koyama T, Zhao ZG, Huang LC, Hoffman K, Conwill R, Penson D, Barocas D. Radiotherapy After Radical Prostatectomy: Effect Of Timing Of Post-Prostatectomy Radiation On Functional Outcomes. JOURNAL OF UROLOGY 203(4):E783-E784, 2020.
14. Hoffman KE, Volk R, Chapin B, Tang C, Allen PK, Anscher MS, Choi S, Davis JW, Frank SJ, McGuire SE, Nguyen QN, Pettaway CA, Kuban DA. Impact of Multidisciplinary Counseling on Awareness of Prostate Cancer Treatment Options. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 105(1):E442-E442, 2019.
15. Philip N, Pugh TJ, Ye R, Hwang H, Wang X, Shah SJ, Choi S, Mahmood U, Nguyen QN, Chun SG, Mayo LL, Lee AK, Tang C, Anscher MS, Hoffman KE, Kuban DA, Davis JW, Troncoso P, Choi H, Frank SJ. A Phase II trial of Hypofractionated Proton Therapy in Prostate Cancer: 3-year Physician and Patient Reported Outcomes. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 105(1):E302-E302, 2019.
16. Frey SD, Hoffman KE, Jhingran A, McAleer MF, Minsky BD, Kirsner S, Arora G, Zaebst D, Robinson I, Roberts T, Patel AB, Olson MR, Gabel M, Bolukbasi Y, Llorente M, de Carvalho IT, Ghafar R, Koong A, Herman JM, Kuban DA. Developing clinical indicators to effectively monitor a large network of radiation oncology practices. JOURNAL OF CLINICAL ONCOLOGY 37(27), 2019.
17. Ludmir EB, Hoffman KE, Jhingran A, Ip MCP, Frey SD, Ning MS, Minsky BD, McAleer MF, Chronowski G, Arzu I, Reed VK, Garg AK, Roberts T, Ashish P, Olson MR, Selek U, Gabel M, Koong A, Herman JM, Kuban DA. Implementation and efficacy of a large-scale radiation oncology case-based peer-review quality program across a multinational cancer network. JOURNAL OF CLINICAL ONCOLOGY 37(27), 2019.
18. Singh P, Hoffman K, Schaverien M, Smith B, Kuerer H. Pre-mastectomy radiotherapy feasibility trial to facilitate immediate autologous breast reconstruction: A prospective cohort within a randomized clinical trial. ANNALS OF SURGICAL ONCOLOGY 26:57-58, 2019.
19. Laviana A, Hernandez A, Zhao ZG, Huang LC, Koyama T, Conwill R, Fuerer I, Hoffman K, Penson D, Barocas D. INTERPRETATION OF DOMAIN SCORES ON THE EXPANDED PROSTATE CANCER INDEX COMPOSITE: HOW DOES THE DOMAIN SCORE TRANSLATE INTO FUNCTIONAL OUTCOME?. JOURNAL OF UROLOGY 201(4):E635-E635, 2019.
20. Laviana A , Zhao ZG, Huang LC, Koyama T, Conwill R, Fuerer I, Hoffman K, Penson D, Barocas D. DEVELOPMENT AND VALIDATION OF A WEB-BASED TOOL TO PREDICT SEXUAL, URINARY, AND BOWEL FUNCTION LONGITUDINALLY AFTER RADIATION THERAPY, SURGERY, OR OBSERVATION. JOURNAL OF UROLOGY 201(4):E630-E631, 2019.
21. Joyce DD, Laviana AA, Zhao ZG, Hoffman KE, Huang LC, Koyama T, Conwill R, Penson DF, Barocas DA. PATIENT REPORTED FUNCTIONAL OUTCOMES AFTER 5 YEARS IN MEN WITH LOW- AND FAVORABLE INTERMEDIATE-RISK PROSTATE CANCER. JOURNAL OF UROLOGY 201(4):E562-E562, 2019.
22. Laviana A, Joyce D, Zhao ZG, Huang LC, Koyama T, Conwill R, Fuerer I, Hoffman K, Penson D, Barocas D. COMPARISON OF EXTERNAL BEAM RADIATION THERAPY AND ROBOTIC PROSTATECTOMY ON PATIENT REPORTED OUTCOMES AFTER 5 YEARS IN MEN WITH UNFAVORABLE INTERMEDIATE-RISK AND HIGH-RISK PROSTATE CANCER. JOURNAL OF UROLOGY 201(4):E561, 2019.
23. Bagley A, Anscher M, Choi S, Frank SJ, Hoffman K, Kuban D, McGuire S, Nguyen QN, Smith B, Smith G, Pezzi TA, Chapin B, Aparicio A, Hess K, Tang C. Factors Affecting Receipt of Non-Definitive Therapy for High-Risk Prostate Cancer: A National Cancer Database Analysis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 103(5):E13-E14, 2019.
24. Ovalle V, Strom EA, Shaitelman SF, Hoffman KE, Amos R, Perkins GH, Tereffe W, Smith BD, Stauder MC, Woodward WA. Proton Partial Breast Irradiation: Detailed Description of Acute Clinico-Radiologic Effects. Cancers 2018, 2018.
25. Stauder MC,Shaitelman SF, Allen PK, Smith BD, Hoffman KE,Buchholz TA,Middleton LP, Chavez-Macgregor M, Caudle AS, Hunt KK, Meric-Bernstam F, Woodward WA. Postmastectomy Radiation Therapy After Positive Sentinel Lymph Node Biopsy and Completion Axillary Lymph Node Dissection. Int J Radiation Oncol Biol Phys 90(S1):S235-6, 2014.
26. Domain D, Hoffman KE, Madsen LT, Pettaway CA, Kim J, Davis JW, Lee AK, Pisters L, Levy L, Kuban DA. Clinical Trial Enrollment in a Multidisciplinary Prostate Cancer Clinic. I.J. Radiation Oncology, Biology, Physics 81(2):S565, 2011.
27. Hoffman KE, Kim J, Davis JW, Choi S, Pettaway C, Lee AK, Domain D, Levy L, Madsen LT, Kuban DA. Barriers to Active Surveillance as a Treatment Choice for Prostate Cancer. I.J. Radiation Oncology, Biology, Physics 81(2):S141-S142, 2011.
28. Hoffman KE, Madsen LT, Levy L, Pettaway C, Pisters L, Choi S, Kim J, Davis JW, Ward JF, Kuban DA. Prostate Cancer Treatment Selection after Counseling in a Multidisciplinary Prostate Cancer Clinic. I.J. Radiation, Oncology, Biology, Physics 81(2):S563-S564, 2011.
29. Hoffman KE, Neville BA, Mamon HJ, Kachnic LA, Katz MS, Earle CC, Punglia RS. Adjuvant therapy for elderly patients with resected gastric adenocarcinoma: population-based practices and treatment effectiveness. Cancer 118(1):248-57, 2011. e-Pub 2011. PMID: 21692071.
30. Nguyen PL, Chen M, Chen RC, Hoffman KE, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K, D’Amico AV. Comorbidity and Treatment Regret in Men with Recurrent Prostate Cancer, 2011.
31. Hoffman KE, Chen M, Nguyen PL, Bennett CL, Sartor AO, Stein K, Kuban DA, D'Amico AV. Factors Associated with a Delay in Diagnosis of Recurrent Prostate Cancer After Radical Prostatectomy, 2011.
32. Beard CJ, Chen M, Arvold ND, Nguyen PL, Ng AK, Hoffman KE. Long-Term Survival and Competing Causes of Death in Men with Stage I Seminoma. I.J. Radiation Oncology, Biology, Physics 78(3):S60, 2010.
33. Arvold ND, Catalano PJ, Sweeney CJ, Hoffman KE, Nguyen PL, Balboni TA, Fosså SD, Travis LB, Beard CJ. Patterns of care for stage I seminoma: a survey of American radiation oncologists. I.J. Radiation Oncology, Biology, Physics 78(3):S193, 2010.
34. Nguyen Q, Levy LB, Lee AK, Choi S, Frank SJ, Hoffman KE, McGuire S, Kuban DA. Risk Factors Predicting Failure And Prostate Cancer Mortality In High Risk Prostate Cancer Patients Treated With Definitive External Beam Radiation Therapy. I.J. Radiation Oncology, Biology, Physics 78(3):S125, 2010.
35. Hoffman KE, Symmans WF, Oh JL, Welela T, Yu TK, Perkins GH, Strom EA, Gonzalez-Angulo AM, Buchholz TA, Woodward WA. Pathologic features Predicting for High Rates of Local-Regional Recurrence after Neoadjuvant Chemotherapy and Radiation Therapy for Breast Cancer. I.J. Radiation Oncology, Biology, Physics 78(3):S97, 2010.
36. Kim MM, Hoffman KE, Levy LB, Master P, Frank SJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Improvement in Prostate Cancer Outcomes Over Time: A Twenty-Year Analysis. I.J. Radiation Oncology, Biology, Physics 78(3):S191, 2010.
37. McGuire SE, Levy LB, Settle SH, Choi S, Nguyen QN, Hoffman KE, Frank SJ, Lee AK, Kuban DA. PSA Response to Neoadjuvant Androgen Suppression Therapy Prior to High Dose Radiotherapy Predicts Survival in Clinically Localized High Risk Prostate Cancer. I.J. Radiation Oncology, Biology, Physics 78(3):S124, 2010.
38. Kuban DA, Nogueras-Gonzalez GM, Hamblin L, Lee AK, Choi S, Frank SJ, Nguyen QN, Hoffman KE, McGuire SE, Munsell MF. Preliminary Report of a Randomized Dose Escalation Trial for Prostate Cancer Using Hypofractionation. I.J. Radiation Oncology, Biology, Physics 78(3):S58, 2010.
39. Nguyen PL, Chen M, Dosoretz DE, Moran BJ, Salenius SA, Braccioforte MH, Beard CJ, Hoffman KE ,D’Amico AV, Ennis RD. The Adverse Impact of Androgen Deprivation Therapy on All-Cause Mortality in Men with High-Risk Prostate Cancer and a History of Congestive Heart Failure (CHF) or Myocardial Infarction (MI). I.J. Radiation Oncology, Biology, Physics 78(3):A350, 2010.
40. Hoffman KE. Medicare Claims Data: Rapid Answers to Big Questions, 2010.
41. Morikawa LK, Levy LB, Choi S, Nguyen QN, McGuire S, Hoffman K, Frank SJ, Lee A, Kuban DA. Relationship Between PSA Failure and Death From Prostate Cancer After Radical External Beam Radiation Therapy, 2010.
42. Morikawa LK, Rajat K, Kanke J, Choi S, Nguyen QN, McGuire S, Hoffman K, Frank SJ, Lee A, Kuban DA. Endorectal balloon in Post-Operative Prostate Cancer Patients: Who Benefits From It?, 2010.
43. Walker GV, Smith GL, Allen P, Perkins GH, Oh JL, Woodward WA, Yu TK, Hunt KK, Hoffman K, Strom EA, Buchholz TA. Population-Based Analysis of Occult Primary Breast Cancer with Axillary Nodal Metastasis. Oncology 24(4 Suppl 3):2, 2010.
44. Hoffman KE, Chen M, Nguyen PL, D'Amico AV. Post-prostatectomy Radiation Therapy in the United States: Patterns of Care. International Journal of Radiation Oncology, Biology, Physics 75(3, Supplement):S90, 2009.
45. Hoffman KE, Abi-Raad R, Ancukiewicz M, Yeh E, Ryan P, Schapira L, Younger J, Smith B, Kuter I, Taghian A. Impact of Interstitial Fluid Pressure, Tumor Oxygenation, and Chemotherapy Drug Sequencing on Response to Neoadjuvant Chemotherapy and on Long-Term Local Control in Women Treated for Locally Advanced Breast Cancer. I.J. Radiation Oncology, Biology, Physics 69(3):S61-S62, 2007.
46. Nguyen P, Hoffman KE. A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of Leuprolide with or without Abiraterone (AAP) and Apalutamide (Apa) post-Radical Prostatectomy (RP).

Book Chapters

1. Kundra, V, Chery LJ, Hoffman KE. Chapter 23 Prostate cancer In Oncologic Imaging. In: 2nd Edition (Silverman), 2020.
2. Moningi S, Pettaway C, Hoffman K. Penile Cancer. In: The MD Anderson Cancer Center Handbook of Radiation Oncology, 2019.
3. Woodward WA, Poenisch, F. and Hoffman KE. Proton Radiotherapy for Breast Cancer. In: In Proton Therapy, 2018.
4. Patterson ML, Davis JW, Kim JE, Hoffman KE, Osai WE, Kuban DA. Genitourinary Cancer Survivorship Management. In: The MD Anderson Cancer Center Survivorship Textbook. Springer, 2014.
5. Kuban DA, Hoffman KE, Corn P, Pettaway C. Prostate Cancer. In: 60 Years of Survival Outcomes at the University of Texas, MD Anderson Cancer Center, 35-43, 2013.
6. Bart JC, Judd LL, Hoffman KE, Wilkins AM, Charles PT, Kusterbeck AQ. Detection and Quantitation of the Explosives 2, 4, 6-Trinitrotoluene and Hexahydro-1, 3, 5-triazine in Groundwater Using a Continuous Flow Immunosensor. In: Immunochemical Technology for Environmental Applications: Washington, DC, 210-220, 1997.